Clinical Trials Browser

OTHER × Everolimus × Breast × Clear all

NCT07340541 2026-05-20

EVOLVE-BDT

Phase 2 Recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05749588 2026-04-16

FUSCC Refractory TNBC Platform Study (FUTURE2.0)

Phase 2 Recruiting

Triple Negative Breast Neoplasms

NCT06382948 2026-04-03

ADELA

Phase 3 Recruiting

Advanced Breast Cancer

NCT07407517 2026-02-12

POLARIS

Phase 3 Not yet recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02520063 2026-02-06

Combination of Letrozole, Everolimus and TRC105 in Postmenopausal Women With Hormone-Receptor Positive and Her2 Negative Breast Cancer

Phase 1/2 Completed

15 enrolled 18 charts

Breast Neoplasms

NCT05826964 2026-01-13

Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer

Phase 2 Active not recruiting

Breast Neoplasms

NCT03032406 2025-07-22

CLEVER Pilot Trial: A Phase II Pilot Trial of HydroxyChLoroquine, EVErolimus or the Combination for Prevention of Recurrent Breast Cancer

Phase 2 Active not recruiting

53 enrolled 12 charts

Breast Neoplasms

NCT01805271 2025-05-14

Safety Study of Adding Everolimus to Adjuvant Hormone Therapy in Women With High Risk of Relapse, ER+ and HER2- Primary Breast Cancer, Free of Disease After Receiving at Least One Year of Adjuvant Hormone Therapy

Phase 3 Active not recruiting

Primary Non-metastatic Breast Cancer

NCT00317720 2025-04-30

Trastuzumab and RAD001 in Patients With Human Epidermal Growth Receptor 2 (HER-2) Overexpressing Breast Cancer

Phase 1/2 Completed

40 enrolled 8 charts

Breast Neoplasms, Neoplasm Metastasis

NCT00253318 2025-04-27

RAD001 Plus Docetaxel in Patients With Metastatic Breast Cancer

Phase 1 Terminated

Breast Neoplasms, Neoplasm Metastasis

NCT02531932 2025-02-19

Comparison of Single-Agent Carboplatin vs the Combination of Carboplatin and Everolimus for the Treatment of Advanced Triple-Negative Breast Cancer

Phase 2 Completed

Breast Neoplasms

NCT02216786 2024-12-02

MANTA

Phase 2 Completed

Estrogen Receptor Positive Breast Cancer

NCT05594095 2024-10-04

SNF Platform Study of HR+/ HER2-advanced Breast Cancer

Phase 2 Recruiting

Breast Neoplasms

NCT06561022 2024-08-19

abemaSNF1/3

Phase 2 Not yet recruiting

Breast Neoplasms

NCT03154281 2024-08-01

Evaluation of the Safety and Tolerability of Niraparib With Everolimus in Advanced Gynecologic Malignancies and Breast

Phase 1 Completed

14 enrolled 12 charts

BreastGynecologic

Breast Neoplasms, Ovarian Neoplasms

NCT03878524 2024-03-04

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

Phase 1 Terminated

BreastClassical hematologyGastrointestinalGenitourinaryLymphoidMyeloidOther hematologic neoplasmPlasma cell

Anemia, Blast Crisis, Breast Neoplasms, Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Neoplasm Metastasis, Pancreatic Neoplasms, Prostatic Neoplasms, Thrombocytosis, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Primary Myelofibrosis

NCT02456857 2024-02-13

Liposomal Doxorubicin, Bevacizumab, and Everolimus in Patients With Locally Advanced TNBC With Tumors Predicted Insensitive to Standard Chemotherapy; A Moonshot Initiative

Phase 2 Completed

17 enrolled 8 charts

Triple Negative Breast Neoplasms

NCT05949541 2024-02-08

BCTOP-L-M01

Phase 2 Recruiting

Breast Neoplasms

NCT05954442 2024-01-16

BCTOP-T-M03

Phase 3 Recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04591431 2023-10-03

ROME

Phase 2 Unknown

BreastGastrointestinalThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Gastrointestinal Neoplasms

NCT00934895 2023-09-18

Phase I/II Study of Weekly Abraxane and RAD001 in Women With Locally Adv. or Metastatic Breast Ca

Phase 1/2 Terminated

27 enrolled 12 charts

Breast Neoplasms

NCT01298713 2023-09-06

Tamoxifen-RAD001 Versus Tamoxifen Alone in Patients With Anti-aromatase Resistant Breast Metastatic Cancer

Phase 2 Completed

Breast Neoplasms

NCT02028364 2023-08-24

PEARL

Phase 2 Completed

Breast Neoplasms

NCT05983107 2023-08-09

Chidamide/Everolimus for PIK3CA Wild-type/Mutant HR+/HER2- Advanced Breast Cancer

Phase 2 Recruiting

HR+/HER2- Advanced Breast Cancer

NCT02871791 2022-08-29

Palbociclib With Everolimus + Exemestane In BC

Phase 1/2 Completed

41 enrolled 12 charts

Human Epidermal Growth Factor 2 Negative Carcinoma of Breast

NCT03805399 2022-08-10

FUTURE

Phase 1/2 Unknown

Triple Negative Breast Neoplasms

NCT04355858 2022-07-26

MULAN

Phase 2 Unknown

Breast Neoplasms, Neoplasm Metastasis

NCT02120469 2022-07-05

Eribulin Mesylate and Everolimus in Treating Patients With Triple-Negative Metastatic Breast Cancer

Phase 1 Completed

27 enrolled 16 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05429684 2022-06-23

Precise Therapy for Refractory HER2 Positive Advanced Breast Cancer

Phase 3 Unknown

HER2+ Breast Cancer

NCT02269670 2022-04-05

Phase II Study of Everolimus Beyond Progression

Phase 2 Terminated

3 enrolled 4 charts

Breast Neoplasms

NCT01499160 2022-02-11

Letrozole and Lapatinib Followed by Everolimus in Women With Advanced Breast Cancer

Phase 2 Terminated

7 enrolled 6 charts

Breast Diseases, Breast Neoplasms, Neoplasm Metastasis

NCT02236572 2022-02-01

Neoadj ph 2 AI Plus Everolimus in Postmenopausal Women w/ ER Pos/HER2 Neg, Low Risk Score

Phase 2 Terminated

17 enrolled 11 charts

Breast Neoplasms

NCT02742051 2021-09-23

A Trial of Neoadjuvant Everolimus Plus Letrozole Versus FEC in Women With ER-positive, HER2-negative Breast Cancer

Phase 2 Completed

Breast Neoplasms

NCT01931163 2021-07-20

NECTAR

Phase 2 Completed

24 enrolled 7 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04212702 2021-01-12

ESR1 Mutations in Asian ER+ Metastatic Breast Cancer on Hormonal Therapy-based Treatments

Breast Neoplasms

NCT02152943 2020-12-19

Everolimus, Letrozole and Trastuzumab in HR- and HER2/Neu-positive Patients

Phase 1 Completed

Breast Neoplasms

NCT02511639 2020-12-03

MAIN-A

Phase 3 Completed

Breast Cancer Metastatic

NCT02344550 2020-07-30

LEO

Phase 2 Completed

Breast Neoplasms

NCT01627067 2020-06-19

Exemestane-RAD001-Metformin

Phase 2 Terminated

23 enrolled 7 charts

Breast Neoplasms

NCT02291913 2020-02-17

Everolimus Combined With Anti-estrogen Therapy in Hormone-Receptor-Positive HER-2 Negative Advanced Breast Cancer

Phase 2 Completed

48 enrolled 13 charts

Breast Neoplasms

NCT01783756 2019-11-12

Phase 1b/2 Trial Using Lapatinib, Everolimus and Capecitabine for Treatment of HER-2 Positive Breast Cancer With CNS Metastasis

Phase 1/2 Completed

Breast Neoplasms, Breast Neoplasms, Male

NCT02376985 2019-10-21

Evaluation of Oral Care to Prevent Oral Mucositis in ER Positive MBC Patients Treated With Everolimus: Phase 3 RCT

Phase 3 Completed

Breast Neoplasms

NCT02109913 2019-10-14

Analysis of Tumor Tissue and Circulating Genetic Material in the Blood to Obtain Further Insight in the Effectiveness of Everolimus When Combined With Exemestane

Phase NA Unknown

Breast Neoplasms, Neoplasm Metastasis

NCT01305941 2018-12-17

A Study Of Everolimus, Trastuzumab And Vinorelbine In HER2-Positive Breast Cancer Brain Metastases

Phase 2 Completed

32 enrolled 19 charts

Brain Neoplasms, Breast Neoplasms

NCT00912340 2018-12-05

Phase II Trial of EVEROLIMUS ± Trastuzumab in Hormone-Refractory Metastatic Breast Cancer

Phase 2 Completed

70 enrolled 12 charts

Breast Neoplasms

NCT01031446 2018-08-31

Cisplatin, Paclitaxel, and Everolimus in Treating Patients With Metastatic Breast Cancer

Phase 1/2 Completed

55 enrolled 12 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT01797120 2018-05-30

PrE0102

Phase 2 Completed

131 enrolled 12 charts

Breast Neoplasms

NCT00855114 2017-12-02

Everolimus in Treating Women With Breast Cancer That Can Be Removed by Surgery

Phase 2 Withdrawn

Breast Neoplasms

NCT02809404 2017-10-16

SPOT

BreastGenitourinary

Breast Neoplasms, Carcinoma, Renal Cell

NCT01520103 2017-08-09

VicTORia

Phase 2 Completed

Breast Neoplasms